Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

<< Previous

Bullboard Posts

Next >>

Post by R_J_on Oct 01, 2020 5:24pm

131 Views

Post# 31655259

End of Month - September 2020

End of the Month (EOM) report for September 2020 for Anavex Life Sciences Corp.
-
AVXL closed on 07/31/2020 at US$4.55
AVXL closed on 08/31/2020 at US$4.24
-
This is a 7.3%, a 31-cent, Gain for September.
-
S&P 500 Index, @ 3363.0 lost 3.9% in September. [8.1% above its MA(200) @ 3110.0]
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's MA(200) ended September at $3.78
AVXL is now 20.4% above its MA(200).
-
News Releases on the AVXL Website in September
-
Use this link to see and read the all of September’s News Releases.
-
https://www.anavex.com/2020/09/
-
Who is the Big Cheese at AVXL?
Christopher U. Missling, PhD, President & CEO
-
RJ

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant